Barinthus Biotherapeutics plc Cash Flow-to-Debt Ratio
Barinthus Biotherapeutics plc cash flow-to-debt ratio. Barinthus Biotherapeutics plc (BRNS) has a Cash Flow-to-Debt Ratio of -0.44x as of September 2025, meaning its operating cash flow of $-10.73 Million could theoretically repay 0% of its total liabilities ($24.64 Million) in one year. Check BRNS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Barinthus Biotherapeutics plc (2019–2024)
Cash flow-to-debt ratio of Barinthus Biotherapeutics plc from 2019 to 2024. Historical debt coverage capacity for Barinthus Biotherapeutics plc across 6 annual periods. Check BRNS cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Barinthus Biotherapeutics plc Cash Flow-to-Debt Ratio by Year (2019–2024)
Barinthus Biotherapeutics plc cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for Barinthus Biotherapeutics plc. For the full cash flow conversion analysis, see Barinthus Biotherapeutics plc (BRNS) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.96x | $-28.94 Million | $30.19 Million | ▲ +48.2% |
| 2023 | -1.85x | $-50.92 Million | $27.51 Million | ▼ -246.4% |
| 2022 | -0.53x | $-14.43 Million | $27.00 Million | ▲ +53.8% |
| 2021 | -1.16x | $-32.58 Million | $28.15 Million | ▼ -464.8% |
| 2020 | -0.20x | $-11.03 Million | $53.81 Million | ▲ +55.1% |
| 2019 | -0.46x | $-18.76 Million | $41.12 Million | — |